31st October 2023 -- Cambridge
Isomerase granted US patent to novel polyketide natural product bioengineering methods
Isomerase is delighted to announce that they have been granted US patent number 11,781,128, a member of a family of patents and patent applications disclosing and claiming novel junctions and methods for bioengineering the important modular natural product polyketide and non-ribosomal peptide systems. The granted claims in 11,781,128 particularly relate to specific junctions which can be used to make more active hybrid polyketide synthases and thereby improve polyketide engineering efficiency and productivity.
Isomerase is an innovation partner in a range of fields, but has particular expertise and technology relating to natural products bioengineering (secondary metabolites) discovery and development. Polyketides are an important class of natural products and includes a wide range of antibiotics, antifungals, anticancer agents, ADC warheads, immunosuppressants and crop protection agents such as rapamycin (sirolimus), erythromycin, azithromycin, clarithromycin, spinosyn (spinosad), geldanamycin, FK506 (tacrolimus), rifamycin, amphotericin, ivermectin, pladienolide and nystatin.
This patent is part of a family of intellectual properties which relate to technologies that the team at Isomerase have developed and acquired and can use on client natural product bioengineering projects to support:
• Development of existing assets - for example inactivating competing natural product pathways in a producer strain, developing robust scalable fermentation USP and DSP processes ready for clinical development or setting up analytical methods)
• Drug discovery to help discover and develop new compound IP and assets, for example by bioengineering producer strains to make natural product analogs.
If you are interested in natural products drug discovery and development, or Natural Product bioengineering, please feel free to contact us via the website or
For more information, please visit www.isomerase.com
Isomerase is a leading innovation partner for all aspects of microbial product and process discovery and development, including leading-edge synthetic biology, natural product bioeingineering, advanced strain improvement of microorganisms, genome sequence analysis, protein and peptide expression and isolation, fermentation and process development, DSP, compound isolation, analytical development and synthetic chemistry. In addition, Isomerase manages other aspects necessary for a commercially successful programme on behalf of partners, such as compound management and shipping and scaled manufacture.
We offer these capabilities underpinned by a portfolio of technology IP, and the combined experience of a core technical and leadership team with a substantive track record of successful product discovery and development collaborations with pharma and biotech companies.
We have supported numerous companies with a wide variety of natural product bioengineering, microbial product and small molecule fermentation and synthetic chemistry projects, helping advance early-stage concepts into valuable development programmes, and then continuing to support their progress to market with process improvement and scaled manufacture.
For more information please contact Isomerase via our contact page.